Reduced risk of gastrointestinal bleeding associated with eupatilin in aspirin plus acid suppressant users : nationwide population-based study
BACKGROUND/AIMS: Mucoprotective agents, such as eupatilin, are often prescribed to prevent gastrointestinal (GI) bleeding in addition to an acid suppressant despite the absence of a large-scale study. We evaluated the additional effect of eupatilin on the prevention of GI bleeding in both the upper and lower GI tract in concomitant aspirin and acid suppressant users using the nationwide database of national claims data from the Korean National Health Insurance Service (NHIS).
METHODS: An aspirin cohort was constructed using the NHIS claims data from 2013 to 2020. Patients who manifested with hematemesis, melena, or hematochezia were considered to have GI bleeding. A Cox proportional hazards regression model was used to determine the risk factors for GI bleeding associated with the concomitant use of GI drugs and other covariates among aspirin users.
RESULTS: Overall, a total of 432,208 aspirin users were included. The concurrent use of an acid suppressant and eupatilin (hazard ratio [HR] = 0.85, p = 0.016, vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding. Moreover, a more than 3-month duration (HR = 0.88, p = 0.030) of acid suppressant and eupatilin prescription (vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding.
CONCLUSION: Eupatilin administration for ≥ 3 months showed additional preventive effect on GI bleeding in concomitant aspirin and acid suppressant users. Thus, cotreatment with eupatilin with a duration of 3 months or longer is recommended for reducing GI bleeding among aspirin plus acid suppressant users.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
The Korean journal of internal medicine - 39(2024), 2 vom: 15. März, Seite 261-271 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Hyun Seok [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4D58O05490 |
|---|
| Anmerkungen: |
Date Completed 07.03.2024 Date Revised 09.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3904/kjim.2023.324 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36583257X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36583257X | ||
| 003 | DE-627 | ||
| 005 | 20240309232043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3904/kjim.2023.324 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM36583257X | ||
| 035 | |a (NLM)38092556 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Hyun Seok |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reduced risk of gastrointestinal bleeding associated with eupatilin in aspirin plus acid suppressant users |b nationwide population-based study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2024 | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND/AIMS: Mucoprotective agents, such as eupatilin, are often prescribed to prevent gastrointestinal (GI) bleeding in addition to an acid suppressant despite the absence of a large-scale study. We evaluated the additional effect of eupatilin on the prevention of GI bleeding in both the upper and lower GI tract in concomitant aspirin and acid suppressant users using the nationwide database of national claims data from the Korean National Health Insurance Service (NHIS) | ||
| 520 | |a METHODS: An aspirin cohort was constructed using the NHIS claims data from 2013 to 2020. Patients who manifested with hematemesis, melena, or hematochezia were considered to have GI bleeding. A Cox proportional hazards regression model was used to determine the risk factors for GI bleeding associated with the concomitant use of GI drugs and other covariates among aspirin users | ||
| 520 | |a RESULTS: Overall, a total of 432,208 aspirin users were included. The concurrent use of an acid suppressant and eupatilin (hazard ratio [HR] = 0.85, p = 0.016, vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding. Moreover, a more than 3-month duration (HR = 0.88, p = 0.030) of acid suppressant and eupatilin prescription (vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding | ||
| 520 | |a CONCLUSION: Eupatilin administration for ≥ 3 months showed additional preventive effect on GI bleeding in concomitant aspirin and acid suppressant users. Thus, cotreatment with eupatilin with a duration of 3 months or longer is recommended for reducing GI bleeding among aspirin plus acid suppressant users | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-ulcer agents | |
| 650 | 4 | |a Artemisia | |
| 650 | 4 | |a Aspirin | |
| 650 | 4 | |a Gastrointestinal hemorrhage | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 650 | 7 | |a eupatilin |2 NLM | |
| 650 | 7 | |a 4D58O05490 |2 NLM | |
| 650 | 7 | |a Flavonoids |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 700 | 1 | |a Nam, Ji Hyung |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Dong Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Yeo Rae |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Yun Jeong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Korean journal of internal medicine |d 1986 |g 39(2024), 2 vom: 15. März, Seite 261-271 |w (DE-627)NLM012627402 |x 2005-6648 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g number:2 |g day:15 |g month:03 |g pages:261-271 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3904/kjim.2023.324 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |e 2 |b 15 |c 03 |h 261-271 | ||